Provided by Tiger Trade Technology Pte. Ltd.

Natera

384.98
-10.5800-2.67%
Volume:898.92K
Turnover:346.89M
Market Cap:55.14B
PE:-280.41
High:392.96
Open:388.00
Low:380.55
Close:395.56
52wk High:437.41
52wk Low:167.99
Shares:143.22M
Float Shares:139.00M
Volume Ratio:0.99
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:30.27
PE(LYR):-252.14

Loading ...

Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares

Reuters
·
Jul 07

Natera Announces Board Resignation Amid Governance Transition

TIPRANKS
·
Jul 07

Natera Director Monica Bertagnolli Resigns to Take National Academy of Medicine Role

Reuters
·
Jul 07

Natera is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jul 07

Natera Says Colorectal Liver Metastasis Test Identifies Patients Who Benefit From Chemotherapy

MT Newswires Live
·
Jul 06

Natera Signatera MRD Test Data in JAMA Oncology Links Chemo to Overall Survival Gain in Resected Metastatic Colorectal Cancer

Reuters
·
Jul 06

Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 03

When Multi-cancer Blood Screens Could Finally Take Off

Dow Jones
·
Jul 02

Movement Alert|Natera Falls 5.1% in After-Hours Trading, Trading at $270.25

Market Focus
·
Jul 01

Natera is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Natera, Aveta Biomics announce strategic partnership

TIPRANKS
·
Jun 29

Natera Partners with Aveta Biomics on Phase 3 Apg-157 Head and Neck Cancer Trial

Reuters
·
Jun 29

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29

Natera - Phase 3 Trial Expected to Begin Enrollment in Second Half of 2026

THOMSON REUTERS
·
Jun 29

Natera Director Herm Rosenman Disposes of 16,530 Shares for $4.13 Million

Reuters
·
Jun 27

Natera Price Target Announced at $310.00/share by Bernstein

Dow Jones
·
Jun 26

Natera Inc : Bernstein Resumes Coverage with Outperform Rating; Price Target $310

THOMSON REUTERS
·
Jun 26

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25